Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy

Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy

Currently, survival of breast cancer patients with brain metastasis ranges from 2 to 16 months. In experimental brain metastasis studies, only 10% of lesions with the highest permeability exhibited cytotoxic responses to paclitaxel or doxorubicin. Therefore, radiation is the most frequently used tre...

Full description

Bibliographic Details
Main Authors: Ignasi Modolell, Angels Sierra, Cristina Picón, Vanessa Hernández, Antonio Martínez-Aranda
Format: Article
Language:English
Published: MDPI AG 2013-04-01
Series:International Journal of Molecular Sciences
Subjects:
brain metastasis
breast cancer
experimental models
radiation
temozolomide
therapy
Online Access:http://www.mdpi.com/1422-0067/14/4/8306

Internet

http://www.mdpi.com/1422-0067/14/4/8306

Similar Items